Adeno-interleukin-3 gene therapy - CrucellAlternative Names: Interleukin-3 gene therapy - IntroGene
Latest Information Update: 26 Jan 2005
At a glance
- Originator Crucell
- Class Antineoplastics; Cytokine genes; Gene therapies; Interleukins
- Mechanism of Action Immunostimulants; Interleukin 3 stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Sarcoma
Most Recent Events
- 25 Jan 2005 Discontinued - Preclinical for Sarcoma in Netherlands (IV)
- 25 Jun 1998 Preclinical development for Sarcoma in Netherlands (IV)